ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG Financials Eckert & Ziegler Strahlen- und Medizintechnik AG OTC Markets
Equities
EKZRF
DE0005659700
Office Equipment
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | -.--% |
| 05-15 | ECKERT & ZIEGLER : Hauck & Aufhauser reiterates its Buy rating | ZD |
| 05-14 | Eckert & Ziegler SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 981.1 | 923.3 | 1,953 | 963.5 | 859.6 | 950.6 | - | - |
| Enterprise Value (EV) 1 | 922.1 | 834.7 | 1,885 | 903.2 | 818.9 | 907.2 | 908 | 873.9 |
| P/E ratio | 44.4 x | 40.4 x | 56.7 x | 32.9 x | 32.8 x | 27.5 x | 25.8 x | 23.3 x |
| Yield | 0.89% | 1% | 0.53% | 1.08% | 0.12% | 1.1% | 1.1% | 1.1% |
| Capitalization / Revenue | 5.5 x | 5.24 x | 10.8 x | 4.34 x | 3.49 x | 3.51 x | 3.21 x | 2.98 x |
| EV / Revenue | 5.17 x | 4.74 x | 10.4 x | 4.06 x | 3.33 x | 3.35 x | 3.06 x | 2.74 x |
| EV / EBITDA | 21.4 x | 17.9 x | 33 x | 16.3 x | 13.9 x | 13.6 x | 12.5 x | 10.9 x |
| EV / FCF | 27.8 x | 29.9 x | 377 x | 285 x | 38.8 x | 133 x | 66.8 x | 18.1 x |
| FCF Yield | 3.6% | 3.34% | 0.27% | 0.35% | 2.58% | 0.75% | 1.5% | 5.54% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,590 | 20,590 | 20,756 | 20,765 | 20,812 | 20,845 | - | - |
| Reference price 2 | 47.65 | 44.84 | 94.10 | 46.40 | 41.30 | 45.60 | 45.60 | 45.60 |
| Announcement Date | 31/03/20 | 26/03/21 | 30/03/22 | 30/03/23 | 22/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 178.5 | 176.1 | 180.4 | 222.3 | 246.1 | 271.1 | 296.5 | 318.7 |
| EBITDA 1 | 43.13 | 46.7 | 57.04 | 55.52 | 58.83 | 66.7 | 72.8 | 79.9 |
| EBIT 1 | 32.06 | 35.74 | 47.45 | 44.54 | 45.45 | 53 | 56.4 | 61.9 |
| Operating Margin | 17.96% | 20.29% | 26.3% | 20.04% | 18.47% | 19.55% | 19.02% | 19.42% |
| Earnings before Tax (EBT) 1 | 31.25 | 32.74 | 46.39 | 43 | 42.31 | 49.9 | 53.3 | 58.8 |
| Net income 1 | 22.02 | 22.88 | 34.53 | 29.28 | 26.3 | 34.5 | 36.9 | 40.7 |
| Net margin | 12.34% | 12.99% | 19.14% | 13.17% | 10.69% | 12.73% | 12.45% | 12.77% |
| EPS 2 | 1.072 | 1.110 | 1.660 | 1.410 | 1.260 | 1.660 | 1.770 | 1.960 |
| Free Cash Flow 1 | 33.18 | 27.88 | 5 | 3.168 | 21.12 | 6.8 | 13.6 | 48.4 |
| FCF margin | 18.59% | 15.83% | 2.77% | 1.43% | 8.58% | 2.51% | 4.59% | 15.19% |
| FCF Conversion (EBITDA) | 76.91% | 59.71% | 8.77% | 5.71% | 35.9% | 10.19% | 18.68% | 60.58% |
| FCF Conversion (Net income) | 150.67% | 121.84% | 14.48% | 10.82% | 80.31% | 19.71% | 36.86% | 118.92% |
| Dividend per Share 2 | 0.4250 | 0.4500 | 0.5000 | 0.5000 | 0.0500 | 0.5000 | 0.5000 | 0.5000 |
| Announcement Date | 31/03/20 | 26/03/21 | 30/03/22 | 30/03/23 | 22/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 |
|---|---|---|
| Net sales 1 | 67.62 | 65 |
| EBITDA | - | - |
| EBIT 1 | - | 12 |
| Operating Margin | - | 18.46% |
| Earnings before Tax (EBT) | - | - |
| Net income | 8.487 | - |
| Net margin | 12.55% | - |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 14/05/24 | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 59 | 88.6 | 68.1 | 60.3 | 40.7 | 43.4 | 42.6 | 76.7 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 33.2 | 27.9 | 5 | 3.17 | 21.1 | 6.8 | 13.6 | 48.4 |
| ROE (net income / shareholders' equity) | 16.9% | 16% | 20.8% | 14.7% | 12.1% | 13.5% | 13% | 13% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 7.25 | 8.91 | 28.9 | 31.1 | 26.3 | 40 | 37 | 17 |
| Capex / Sales | 4.06% | 5.06% | 15.99% | 14.01% | 10.68% | 14.75% | 12.48% | 5.33% |
| Announcement Date | 31/03/20 | 26/03/21 | 30/03/22 | 30/03/23 | 22/03/24 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
45.6
EUR
Average target price
62.5
EUR
Spread / Average Target
+37.06%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.98% | 7.32B | |
| -9.44% | 4.46B | |
| +1.27% | 3.18B | |
| +9.21% | 2.19B | |
| -35.17% | 986M | |
| +6.05% | 921M | |
| -54.92% | 712M | |
| -28.46% | 636M | |
| -36.47% | 623M |
- Stock Market
- Equities
- EUZ Stock
- EKZRF Stock
- Financials Eckert & Ziegler Strahlen- und Medizintechnik AG
